Clinical Trial Update: Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating an allogeneic GM-CSF vaccine with lenalidomide in myeloma patients near complete remission has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• GM-CSF vaccine (allogeneic) (granulocyte-macrophage colony-stimulating factor vaccine)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2019-01-15